Skip to main content
Amphastar Pharmaceuticals, Inc. logo

Amphastar Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · AMPH ISIN · US03209R1032 LEI · 54930055TH0ZLSAQMJ38 US Manufacturing
Open in API
Filings indexed 916 across all filing types
Latest filing 2018-05-10 Interim / Quarterly Rep…
Country US United States of America
Listing US AMPH

About Amphastar Pharmaceuticals, Inc.

https://amphastar.com/

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing technically challenging medications. Its portfolio includes generic and proprietary injectable, intranasal, and inhalation products. The company specializes in complex medications such as biologics derived from living cells, proteins, and interchangeable biosimilars. Amphastar also develops innovative drug delivery systems and proprietary technological platforms for various routes of administration.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2018
2018-05-10 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 9, 2018, by Amphastar Pharmaceuticals, Inc. It announces the issuance of a press release with financial results for the quarter ended March 31, 2018. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes the press release as an exhibit. The text explicitly states that the information is not deemed "filed" for certain regulatory purposes and is a current report. The document length is 3338 characters, which is relatively short and consistent with an announcement rather than a full report. Given these factors, this document is best classified as an Earnings Release (ER) since it announces quarterly financial results highlights via a press release, which is typical for 8-K filings reporting earnings.
2018-05-09 English
4
Director's Dealing
2018-04-23 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A Proxy Statement filed with the SEC, specifically titled as a Definitive Additional Materials for the Annual Meeting of Amphastar Pharmaceuticals, Inc. It includes detailed voting instructions, meeting date, location, and proposals to be voted on, such as election of directors and ratification of auditors. It references proxy materials and an annual report but does not contain the full annual report itself. The document is about soliciting shareholder votes and providing proxy information for the annual meeting. This matches the definition of Proxy Solicitation & Information Statement (PSI). The document length is over 6000 characters, indicating it is substantive and not just a brief announcement. Therefore, the correct classification is PSI with high confidence.
2018-04-18 English
DEF 14A
Proxy Solicitation & Information Statement
2018-04-18 English
4
Director's Dealing
2018-03-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.